Study on the Effect of Feeding Tube Nutrition During Pre-Surgery Treatment on Complications After Surgery for Esophageal or Stomach Cancer
Led by University Hospital, Bordeaux · Updated on 2026-05-13
670
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Malnutrition is commonly seen in patients diagnosed with esophageal or stomach cancers, affecting 65-80% of cases. It is linked to higher risks such as increased mortality, more postoperative complications, greater toxicity from chemoradiotherapy, and lower survival rates. Malnutrition may worsen during neoadjuvant treatment due to side effects like diarrhea and taste changes. There is currently no clear guidance on the type or duration of nutritional support during this treatment phase, and its impact on postoperative outcomes remains unclear.
This observational study compares patients who receive enteral or parenteral nutrition through feeding jejunostomy during neoadjuvant treatment to those who do not receive such nutritional support. The goal is to evaluate how this perioperative nutritional support affects the rate of postoperative complications. Patients are grouped based on whether they received artificial nutrition during their treatment. The study focuses on assessing the presence and extent of postoperative complications within 30 days after surgery.
Participants will undergo surgery for esophageal cancer while being monitored for their nutritional status before and during treatment. Researchers will track postoperative complications using the Clavien classification system at 30 days post-surgery. The study involves observing outcomes related to nutrition and surgical recovery without altering standard care. Participants health status and treatment responses will be evaluated throughout the study period to better understand how nutritional support influences surgical outcomes.
CONDITIONS
Brief Title
Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer
Research Team
C
Caroline GRONNIER, PhD, MD
V
Valérie AURILLAC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patient not malnourished at the time of management
Patient who did not receive neoadjuvant treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Duration of neoadjuvant treatment
Participants who undergo routine care are observed during neoadjuvant treatment, with or without enteral or parenteral nutrition.
Visits as part of routine clinical care
Surgery and Immediate Post-operative Care
Duration - Up to 30 days post-surgery
Participants undergo surgery for esophageal or stomach cancer followed by immediate post-operative care.
Approximately 1 to 2 visits during hospitalization and early recovery
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Using 18F-FAraG PETCT Scans to Detect Tumors and Predict Treatment Response in Esophageal Cancer Patients Undergoing Chemoradiation
Phase 12a Study of 64Cu-LNTH-1363S PETCT Imaging in Patients with Sarcoma or Gastrointestinal Tract Cancer
Evaluating Safety, Dosage, and Imaging Correlation with FAP Expression
Phase 12 Study of MDNA11, a Beta-only IL-2 Therapy, Alone or With Pembrolizumab for Advanced Solid Tumors
Phase I Study of Cardunizumab Combined with Pulsed Low-dose Rate Radiation for Recurrent Lung, Esophageal, and Cervical Cancers
Phase II Study of Camrelizumab with Chemotherapy Before Surgery for Esophageal Squamous Cell Cancer to Preserve Organs
Study of Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy Using ctDNA Monitoring
for Inoperable Esophageal Squamous Cell Cancer in Adults Aged 18 to 75
Phase 1 Study of IM-1617 to Test Safety and Effectiveness in Adults With Advanced Solid Tumors
Phase 2 Study of Zanidatamab for Previously Treated HER2-Expressing Solid Tumors
Evaluating Safety and Effectiveness in Advanced Cancer
Phase II Study of HLX43 Drug for Adults With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Who Did Not Respond to or Could Not Tolerate Standard First-Line Treatment
Phase II Study Evaluating Multiple Drug Combinations for Advanced Esophageal Squamous Cell Carcinoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Preoperative Nutrition Intervention in Patients Undergoing Resection for Upper Gastrointestinal Cancer: Results from the Multi-Centre NOURISH Point Prevalence Study.
A systematic review of the effect of preoperative nutrition support on nutritional status and treatment outcomes in upper gastrointestinal cancer resection.
Irene Deftereos, Nicole Kiss, Elizabeth Isenring...